ESPR - Earnings call transcript Q2 2022 | Esperion Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode.

Following the presentation, there will be a question-and-answer session. Be advised that today's conference call may be recorded. I would now like to hand the conference over to Tiffany Aldrich, Senior Manager, Corporate Communications at Esperion. Tiffany. ahead, go Please

Tiffany Aldrich

Communications or contained differ and Good management forward-looking Results XXXX. welcome our Call. is Actual and to today's filings. forward-looking due information and and webcast. the Securities that the in Tiffany Carmen. August want Esperion. Quarter press that The by remind qualified to I Act. Litigation I this and SEC Esperion's today our no the XXXX Aldrich, callers Corporate of from conference obligation will this content only part Financial with Company making statements I'm the here Harbor entirety live time-sensitive morning information you, accurate conference at uncertainties statements. covered to materially that I forward-looking and the Second am be team Thank date statements Update to is on could or revise discussed broadcast, call provisions call stated any of in are Safe business. the this contains circumstances We These results risks call after Reform release undertake events caution their statements under of or the update implied of Private those listeners the date by forward-looking of cautionary associated X, of as to reflect statements the Conference

Investors recorded are found morning reminder, be call. archived. a within copy detailing today's As section. of being issued www.esperion.com and content A a at Media conference webcast and release the the call We press this this and can

call prepared with comments the for questions. your begin will and then We open

speak for corporateteam@esperion.com and time turn CEO; Eric Dr. be some Chief from With the follow-up call over available Officer; call, are questions. Department. JoAnne Officer; Ben now Sheldon to Please team and to e-mail Sheldon the for will Foody, President Chief today to BJ the Sheldon? Swartz, Strategy Medical us Following Officer; I team. Koenig, Commercial Halladay prepared Finance will schedule remarks. with Chief Warren, our today's

Sheldon Koenig

everyone. speak highlight exciting of focus in to Thank Tiffany, remaining year you and for Esperion areas the and about good morning, XXXX. significant you, of today It's progress for second our quarter this our incredibly transformational to

while are to achieved our results early in to date. consistent We first to quarter schedule line inflection XXXX. drive pleased We and CLEAR report announce are top XXX% organization that the we most point rapidly continuing Outcomes the Outcomes accumulation on have approaching growth, trial unprecedented CLEAR in for MACE-X significant remain for to

site deliver has We and oral presented database from primary quarter. as medical and study and major of a be term driving research payer of visits, continue execute make conducted to would XXX launch the this label to prominent the in a statins a quarter Board share and the CLEAR reduction. catalyst business market Scientific same to to our time, early our conference for in unison are lock longer on market and be of to sites and expanded innovative our November. the therapy We releasing plans in we working commitment collection have improved first LDL Advisory at exponential results our the for diverse and exponential statement of to brief through represents readout growth both growth our over with experts potential for share. R&D positive provider and and NEXLIZET. the comprehensive entire pipeline unlock on for is plan global The acid data CV flawless market QX healthcare part indicated group validated upcoming preparing significant since that our XX,XXX top project patients. to quality, the risk in assembled line these study a for closeout encompassing organization and results in scientific scrub A and complete trial with accurate the data access large X,XXX and Day endpoint ensure database at ensure data you to NEXLETOL lowering The bempedoic patients Outcomes At Outcomes positive ensuing only for large reporting latter the study

during launched UK, launched sales. reported and cumulatively was launched markets Austria of Our NUSTENDI and and XX,XXX Luxembourg, quarter in quarter treated second territory of Belgium. was The reimbursement have partner, include XXXX, Daiichi for European XXXX NILEMDO with and Spain strong patients. at their Germany, growth the least in Switzerland market Sankyo previously second private

our Otsuka million advance to year-over-year forward of which pull driven XX, ended Web continued trial. our XXXX. million, financial the million, XX% for release report the $X.X this $X.X and XX, its ended the also results year-over-year containing million focus in up less X. year-over-year. Earlier Phase plans June XXXX XX% was year-over-year, announced the bempedoic acid cash operating year-over-year XX, we has compared second up six and pleased X now June six for we Royalty $XX.X product resources to in from the on the XX% continue months second today, Outcomes ended XXXX, by up million quarter available U.S. $X.X the in and June to XX% trial the XX.X line June site. transformative fall territories. for for efficiently In our million our that ended Phase XXXX, second continue quarter and quarter the first and allocating advance achieve quarter, for in previously am a revenue Additionally, revenue of the cost half country in partner we launches launched of the our of XXXX, into second XXXX of compared quarter operational $XX of XX, new press on of was spent up I as is half growth results issued Investor months CLEAR the plan to to to we first expenses top savings XXXX, program dose-finding readout our have

and grew our million continue NUSTENDI XXXX, year-over-year for to NILEMDO the Combined, partner of ended million geographies. royalty and launching partner was a and new XX, $XX.X for XXXX, June We months decrease one-time six XXXX. expect milestone second ended June second XX% $X.X a quarter this decrease revenue XX% million to of in XX, year-over-year, to quarter total payment revenue was $XX.X a adjusting ended partner XXXX. to of June When second attributed the booked large quarter for that revenue XX, XXX% payment, in

million quarter of XXXX, quarter XX, for increase million second the compared after for revenue total June of payment. ended for the $XX.X the upfront Finally, second to XX% an one-time year-over-year was approximately XXXX $XX.X adjusting

revenue, our largely by Turning decreased inventory to the margin U.S. an from a percentage as Gross lower purchase in expenses. international partners, our sales. a driven of than of increase which margin has

months as driven $XX.X acceleration year-over-year. ended for were and XX, an margin for the The $XX.X over reach XX, reflect the XX% state million, SG&A a ended June year earlier XX% decrease ended the expenses Outcomes of year-over-year long-term to the These year-over-year transformation second to implemented $XX.X second of year-over-year. X% months rapid of increase an XXXX, CLEAR year. $XX primarily related increases million this savings to June quarter steady of expect improve compared XXXX XX, XXXX, a closeout half were We million XXXX. the the QX in the and of quarter June study by R&D were expenses first million for XXXX, shipments success June from the the increase decrease six the of for the for XX% ended plan XX, a of decreases XXXX. expenses of six

available $XXX.X with $XXX.X XXXX. of million cash, million As June equivalents, restricted for totaled sale on cash December compared XXXX, and investment XX, cash securities XX,

well runway completion and that are of without Outcomes future $XX results. our and readout We operations fund following CLEAR the million the anticipated restricted trial even continuing extends and of to cash through capitalized those foreseeable our continues anticipate for cash the

Our XXXX the year for remains full operating unchanged. guidance expense

a $X harvest LDL in paradigm a therapy expense expenses and million million be highlight milestones combination continue These $XXX $XX million with lipids year risk to including billion inclusive hypertension over of and revenues be readout to expenses to positive foundation Outcomes We diseases, anticipate NEXLETOL of $XXX cardiovascular chronic for be until $XXX is non-cash of between trial. R&D our catalyst full with approaching in I estimates significantly CLEAR mid in we significant a between potential close, higher the an million in part this as To diabetes. story compensation year. cholesterol $XXX is partner patent approach a are are expected most our stock-based XXXX to We believe reduction. we approximately of shift upfront to want and to XXXX during to of that of SG&A to are expiry Early million. management the incurred

patients updating products have their forward are cholesterol Our you company leading for death milestone and We Therefore, new same on opportunities for are to Q&A. continued today joining with Operator, cause to to much address crucial we poised worldwide. you way. an opportunity support we to a for even of goals. address now interest our progress in Esperion. Thank and in the the help for as with our patients your all early journey begin we chapter help combination to potential our therapy near the ready LDL entirely more reach in look

Operator

Thank Instructions]. you. [Operator

question open. Mr. comes your your first Please is Yee go mute Jefferies. ahead. from Please Yee. Our Michael, check line Michael button, with

Sheldon Koenig

need We're ready, hear just We Mike. you. to

Operator

question? continue the Maybe requeue. Can to next I he's with trying

Sheldon Koenig

can come Yes, that back would be as Mike, to we as long great.

Operator

question. moment One for problem. No our next

We with ahead. have Cowen. Thome from question go a Please Joseph

Joseph Thome

extensive and I you thinking taking morning physicians work there about level of you're in for second quarter, looking potential I'll giving kind in is question. patients? for a think kind my sufficient? going are a therapy little as looking you CV sales mentioned that seeing set risk to for you reduction any the benefit Maybe Good more the just there. of in infection, Hi, you a Or some just anything know doing thank use the in is order be guidelines? of bit trial be more to their Outcomes numbers to

Sheldon Koenig

Yes. Joe. Hi,

of morning thank for and you all, good First the question.

it's I a bit of So think little both.

waiting it for Outcomes. are I Outcomes also for obviously result, looking something the is certain and positive. they And a that is think

remarks, at outcomes. if discussion, But we reduction. there's, for Commercial about just two study did, perspective, to academic better looking powered do perspective to research Officer very And when then in physicians residual previous words, level risk as physicians study an you examine maybe also a There's statistical common academic From talking Chief be market speaking out, will, we think is our always will We'll mentioned add from metrics, are significance, XX% subgroups, in there's think and to an reads I I'll academic prescriber. of different I a with some the that. even for And lack for be et quantitative also an conducted this looking levels. to in Payers color that. that this. large and I cetera. my mind, have that

Eric Warren

question, so of Thanks, of multiple inflection. Yes, your is is the flavors which for, this that level looked Sure. found XXX Joseph. the what powered the significant experienced at we HCP study. at is we payer we Thanks study level And in XX% Sheldon. reduction, quant which base, for reduction, that that and

different at outcome. also flavors looked of We potential

study we encouraged the level is impact, of see again, the that the if for, results value. saw you we I'm base study. really at by from powered will, XX% the that And that significant So

Joseph Thome

maybe if key I inflection Perfect. to that's driver just the more, going be here. And Obviously can. then one

when really interim? you there there, bit, the is the you Are are the though, try outcomes therapy? of teams change can get payer anything even in physicians the discussing structure I Is more scripts near and and just unlock able that anything with guess? sales and in can physicians then, to you're to else saying a are beyond and grow little need to they we Before out term or the there kind your the do obviously

Eric Warren

Yes.

So Joseph, Eric again. it's

authorization for a scale to the you future as of and made commercial anticipation really decision of going the October X% say, growth deliver we actually program resources really HCPs our CLEAR the prior continue I our amped be middle little that. navigate environment that create bit We've to structure with catalyst 'XX, Outcomes reduction barrier, year the our the So barrier bang individuals for of help buck. prior of quarter. that implemented to And you expect some that to will. consistently of closer. that authorizations a breaking The help the a and prior that's in authorizations the deployed and very last program. up this the but of from CLEAR bit though, for real Labcorp footprint of significant HCPs. growth back is CLEAR been difficulty challenge Outcomes, to solve we've we and current or fact if a now, investment Outcomes PAs. associated associated in that most recently in will in our a know We've kind this Prior able is authorization the volume to with burden footprint, really with just conscious in We've data,

Joseph Thome

very much. Perfect, very helpful. Thank you

Eric Warren

welcome. You're

Tiffany Aldrich

we can ask again Mike see a question? able if to he's Operator, to try

Operator

[Operator Instructions].

Sheldon Koenig

of issue. Okay, type having some technical

Operator

see him, not do I sir. Yes.

Sheldon Koenig

Okay.

question. Next

Operator

next our for moment One question, please.

Stanley. comes Please question go ahead. with next Hung Jeff Our from Morgan Mr.

Michael Riad

hearing updates on or you engagement more returning Mike has that is for This at with offices, all? physician Riad Are you Jeff stabilized patients any Hi. Hung. to us HCPs? the process Can provide on

Sheldon Koenig

--? you Eric, to do want

Eric Warren

thanks Yes. and for Good questions. your morning,

environment “more a in the from need there's a to returning marketplace. perspective is also the to there still challenging but of needs lot that normal,” and unmet So be addressed apathy cardiovascular that is

patients to are So the returning office.

with representatives does that and apathy sales there need to more be the our more. are still addressed. able to market HCPs is Our But in interact

Michael Riad

up, maybe quick And if could. Perfect. follow just a I

of Would to for For next the mentioned, adherence to you that actually this what main you step like as think program be increasing I you programs the increase adherence. on program it's see and drivers are the had able out looking this? for

BJ Swartz

Swartz. take that BJ It's question. I'll

products Medicare shortest what physician period even is still, as we has significant burden have the commercial a been the not navigator get see allowing patients of step XX% though the we and program, prior time. in far it's coverage, next such authorization coverage the As to

the So payers shortest to to time. have support the partnered product to in Labcorp field. with the is hand. in assisting the mentioned, and get driver in a hand with stay his the those the hand And on just, in physician the to will ensure gets prescription glove program for prior group that period patients when puts field biggest until really do Eric We authorizations had pad patient their offices reimbursement work prescriptions the the as of with

And so about that that excited we are program X. off July kicked just super

Michael Riad

Awesome. and again Thank so much accumulation. you congrats on XXX% reaching

Sheldon Koenig

Thank you.

Operator

we line Michael ahead. have our of Jefferies question, for please. open. Thank with you. One All next moment go right, Mr. the Yee Please

Michael Yee

Hi, you hear morning. guys. me? Can Good

Sheldon Koenig

Yes, great. Hi, Mike.

Tiffany Aldrich

Mike. Hi,

Michael Yee

like Outcomes back then questions, on Sorry the to Two going about on one I that. study. Zooms. commercial one and thinking the about

commercial, X.X%. I the On know grew it

about were inventory any going was net Just to than figure gross lower to there just trying number on net amounts, quarter? so wondering out to was actually bit a little if the changes in have there. or of will reported the what some quarter-to-quarter Are The out market, there first get study traction valid when reads changes? it quarter, know the thinking all take that. then any time And label you the and I on said in that to Outcomes to early historically

different you one, think of Thanks. will And seek. capital the take I us, is you out time. the would but that's to just that's the how remind remind us I push coverage are some to me, foresee to about Can warrant capital there different avenues that for Outcomes? just scenarios that know So there, talk one

Sheldon Koenig

Sure, will do.

for apologize line and I'm glad of all, first could your again any there, Mike, unmuted difficulties. we get So technical

we come And to Regarding a in had One at the with that it two gross see Medicare It we things actually initiated your win as of relates the coverage. contract we through contract. was to quarter. occurred question started to a Cigna. volume net, that was

step when we have being forward the the we've the that coverage the during the also us. Cigna Today, pay Outcomes for what gap MACE-X big been win we a announced to we accumulation, Medicare describing had win, in only for XXX% to as consistently but the inflection the an fact as point again had that also not us, Of quarter, view that's one CLEAR for we quarter. study We future.

prescribing reads CLEAR to the GTN. our that. will step stabilize say up, reduce that once us we're that's have I because help really also bring actually to So going And study to forward our volume one allow what's more that's move of closer fees volume significantly to to And I distribution that as out. increases for would going well.

as this to and like we would poised events these mentioned we moving net. and us relates coverage merit that, any see that at business, again And well the Medicare X.X%. our growth forward, consistent that is volume to stabilize inflection we're the it been occurred the were of pharmaceutical Outcomes to that having win So and point study gross as of will business. really for happy year. Cigna be doing in growth our allow to is and also CLEAR gap you But we've through that cost And the other demonstrate volume continuous saying consistent and

capital and come do of et at of and As it price coverage, relates the warrants cetera, we so that did raise December with to the warrant last $X. a strike strategy did

in you value $XXX details, giving hand, believe roughly They go our can not a getting we to have a they're different as we're If have that in on expiry forward. it CLEAR total at them. once strategy, that two-year we of pathways the relates Outcomes capital that of order the warrants, explicit capital although those look million. the we to lot we And have need move study we

once CLEAR runway what But CLEAR study. we're be want have we As we Outcomes the the to as I positive at capitalized and will well end study capital prepared to use looking mentioned it some Outcomes do study. post bringing remarks, levers we in to of our in our relates the

Michael Yee

guys. Thanks, Okay.

Operator

moment our for please. question, you. One Thank next

Jessica go from comes JPMorgan. ahead. question with Fye next Please Our

Jessica Fye

my Thanks questions. guys. for Hi, taking Good morning.

research, through once about market up about suggest patients in your of available? the First sort and you does expect comments CLEAR Outcomes the what Mike's like based it even NEXLIZET price Outcomes there, this LDL it on data about and population? think about can change of Second, hard net meaningful on upon on of scale LDL potential higher Outcomes following the can do you the of reduction distribution? one data the is beyond one question, utilization about in expected you us are in the Thanks. market how following achieve available price the magnitude your enrolled that walk net research once indication NEXLETOL baseline it's to hand, reduction in the event you On is is or third, that changes But just less maybe improving economies your and payers price move from that any data. of irrespective volume? new seems And more

Sheldon Koenig

do want you Absolutely. Eric, to start?

Eric Warren

Great. morning, Jess. Good Yes.

the earlier, So and the that is quant. we And categorize and the XX% participated I'll came them in which from the powered to increases or these with of that the saw study penetration in research per interviewed market that base that penetration that exponential for. other question regards at study, level increases came exponential benefit in HCPs -- we ultimately and just as

We HCPs product. also that saw the improvements, significant for criteria of utilization both it well improvements to breadth coverage much prescribe improvements from the easier in a will payer make perspective as the in as management

JoAnne Foody

much question. Jess, this for you is Thank JoAnne. your so

QX as bempedoic the the reduction events in about based study, say forward we think To we believe all hit your the results in thrilled a line on to accumulation top you know are and regarding are know, powered reasons that for to CVOT I'll really acid. is of XXXX. XXX% looking and I question study, that MACE-X confidence cardiovascular absolutely we've our for XX%

and trial, the only unique any deciliter. I that population highest but not further diabetes, XXX as a patients is tend very reduction drugs. think that we high, smart at XX% statin. a non-statin and obesity in of now these given the think hyper look high responders these population by We know patients [indiscernible] cholesterol take XX%. pre-diabetes to to rates per And being though the the of It patients If we this, that understand LDL recent in published, conducted is analysis milligrams we to unique. a outcomes able as see LDL potential to not of the that like cardiovascular risk well it's as be cardiovascular closer trial with has our about very

this the the potential XX%, at is in oral emphasizing as confident forward. label having move forward community. highly needle to non-statin it's powered be results study, hopefully first that are And in previously we we positive and as risk we So bempedoic a to with enough and again, outcomes reduction move the that having therapy clinical look cardiovascular Eric mentioned, acid

Sheldon Koenig

She's And net just regarding beyond JoAnne. Thanks, for then, answer I'll economies your on improvement that. scale, price and demonstrate BJ? Jess, we BJ that. have can Great. question how working of meaningful actively

BJ Swartz

Jess. you, Thank

that person significant Payer at growth. mock recently GTN. CLEAR. Board factor As And Advisory the reduced. we a a unlocked, volume standpoint, hit is that that Jo actually increase trajectory and of volume will our mentioned, had fees, in the readout the and hit wholesaler fees But reducing That's just the as significant of payer and with will all those DSA the P&T, payers unlocked be breakeven volumes in are that profitability P&T. also another as with agreed contracts then a in be mock place the from We conducted a

prior team will the their to Outcomes that. the And Again, hand work with with And Labcorp to in of as that in the field see so reimbursement demand patients CLEAR we on payers about for payers. starting UM excited the interim, are based support we're readout criteria also we start glove very even look now. mentioned, partner at that to

Sheldon Koenig

get which Aspen somewhat we've so just the week had us, increase in hub authorization ever recently just in also for this We offices program. patients as physician's past helps a facilitate seen drug. we've is talked seen one they prior physicians would the we've the And alone. patients over fulfillment, in for actually actually highest that and or XXX can mini but week we have this add, so, about before, of I have

promising as really move we we're So awareness this grows. starting this and very also forward is, and see something to again,

Jessica Fye

you. Thank

Operator

next moment One for please. Thank you. our question,

proceed. next comes Judah Our Credit Please with question Suisse. from Frommer

Judah Frommer

guys. Thanks you potential the Could timing for potential the then And taking Good then around us morning. the release changes call of you out guideline label and change? question, did just in UT of new that left in does How another it to you data terms going on that real-world ensuring tackling collected, seem that? the guidelines. like be Southwestern do you there's plan to remind

Sheldon Koenig

JoAnne?

JoAnne Foody

So, so much. Judah, thank you

So U.S., be right, as Then as improve will reduce our CVOT and then Association, from will then on with the from label American an product as to would we anticipated mentioned, first label College bolstered XXXX. anticipate imagine available outcome that patients potentially anticipate Society Cardiology, of many it data whether for forward. for the cardiovascular data, European of in publicly label the of the or we XXXX. also we Understand, an the those authorizations then us currently American as guidelines, we we the Cardiology of being submitted that increased within of XXXX. or potential half though, the by that With will updated, anticipate and Heart in prior are of trial QX possible cause which be the move guidelines utilization we to quickly within filed be thereafter,

to So for the critical we organization, we as see really the and out therapy as for for this get a patients inflection them. providers

Judah Frommer

providers think your alert you go and asking force to increase I another Okay. authorization out do guideline And is question, have do or that's to sales utilization, guidelines updating prior enough the enough way to guess my as well? burden? reduce of

JoAnne Foody

think to that to engage change So, having the domain guidelines. to Judah, the payer of prior enough, our can payers is in that and the strategy first, study public to BJ to conversations. guidelines speak I And more irrespective

BJ Swartz

Yes.

be with the it the with But the payers all societies resources. to of large to and always guidelines, look certainly In So other also look is the validate to readout they associations. helpful. going meantime,

So authorizations their Payer the had we mock think us utilization they criteria. in be guidelines I soon recent that that Advisory saw the validating told the area one as well in as as validating just UM a would and from again, our P&T, tremendous was changing that advisors that that prior Board

Judah Frommer

Great. Thank you.

Operator

question, One our next moment for please.

& from Our Belanger Serge with next question Needham comes Company.

Your line is open.

Sheldon Koenig

Serge. Hi,

Serge Belanger

Hi. Good morning.

on study of European It the time looks the launch. Just out. ongoing the Outcomes reads a by couple major in markets the will be product questions all the available like

Just curious in Outcomes as share market kind if improved the with U.S.? in do positive Europe you of in same inflection you access expect the a and expanding study

Sheldon Koenig

Sure.

are or markets have will correct very launched. of successful. Again, launched most you that Sankyo has in the So, major either be Daiichi been Europe,

the as you headwinds the to us reason a I a in the is have a that to one tolerated having the have launch U.S. dose that those Europe reduce is the comparison U.S., study. in to maximum relates U.S. it fact States. of patients patients marker the of that label, CLEAR EU almost matter the patients biggest in to of identify U.S. drug label do of also will the And for Upon the United our those ASCVD, have And As have the be on maximum not elements, actually label look in tolerated at they actually we identified ASCVD, Outcomes because which when for they in here as to here their fact, a as and us we do hurdles go the be the having of getting why statin, say away. those the of as statin is hurdle. a will dose when

having not risk back that the reduction having and deciliter. is getting LDL demonstrate at And cardiovascular it the and post that four more upon products launched which to from think dramatically we're in It's can this and study, outcomes, in risk. a the be success looking of of or study milligrams outcomes have, have per different already other products an only based just looking residual that a to they whether uptake, your reduction question, fact hsCRP, again, show Outcomes question, outcomes Europe, of in unique we Serge. the you is relates have previous especially see a median that in also other that of JoAnne inflection that, Now XXX perspective follow-up at looking mentioned that close Europe if actually as we're Europe, that than level know, you always years, you at very as there's U.S. as lowering a But areas time glucose lipid to

So Sankyo partners fuel continue and our this their help will Daiichi definitely success. to

Operator

your Does Serge? answer question, that

Serge Belanger

Thank It you. does.

Operator

Thank you. moment question. for One our next

Butler Jason from comes question JMP next Securities. proceed. Please Our with

Jason Butler

Hi. for the taking Thanks question.

establish you on lifecycle noted that the franchise? of that the Board, talk management focused understand might Scientific potential you to longer just CLEAR for when I Obviously, the to lifecycle you fully Just able be the Advisory But Outcomes with you're evaluate can now. you management. opportunities right

Sheldon Koenig

we can. Yes,

Sorry, were of first Jason. about phone people yes, Board in and moving Board. that our the here. we're our all, Scientific we the really that the Scientific excited are Advisory But have Advisory fact We

will take having an to that's we in R&D We be place going Day mentioned November.

yet. the here have date Esperion, we pipeline. do interesting given haven't specific a at very But We

really talked it We about before. have never

have We a ACL. second generation

as the we'll forward We some with But of be the that have also move JoAnne an maybe oral thinking just we highlight of I'll have PCSKX. SAB. things

JoAnne Foody

best our this Dr. for up expertise as co-chair Scientific so that our Advisory you has in thrilled Advisory ensure and again Board to had to Board. our of deep Peter was the experience pipeline. assets renowned that the Yes, much. are felt this direction critical we really We really internationally Scientific We thank researchers, including with have a a set to Libby

our but platform maximum all best implications of cardio generation bempedoic for next metabolic that our leveraging lyase to technologies, and and to disease, bring scientific value with acid the will, brought reaching cardiovascular, the just in their broad if as the NASH, broad The ATP-citrate set not first ensure expertise advisors the opportunities such approaches only And to you of being in assets. diverse generation in inhibitor, being pipeline the be in reflect to oncology, a broad kidney and has even and features, clear, that range. next

again, our have phases. in also forward oral inhibitor, We moving PCSKX preclinical

in opportunity Development again, on Research Day So focus tuned where an for November stay to and that. have we'll

acid. we once the with the forward top more to CLEAR Outcomes, information lifecycle As well deeply we as have management opportunity as from about bempedoic move line think

Jason Butler

question. the taking for Thanks Great.

JoAnne Foody

welcome. You're

Sheldon Koenig

Jason. Thanks,

Operator

One question. Sachs. now next Thank Paul moment proceed. Please is for next with you. our Goldman And Choi from our question

Paul Choi

MACE-X on questions us, achieving Have discussions just authorization of payer you earlier? top data Hi. working your you any Good data? study. your on scheduled you Are for referenced events and line will please. top just them post or the barriers early you improving few A these prior -- line the already XXX% for in that congratulations after meetings are and scheduled, morning your 'XX the to schedule access have still from

BJ Swartz

in question. that are with having meetings payers, constant improving it's for prior BJ. as our criteria engagement we now, absolutely scheduling well. but Paul, UM just you We to the are Thank your those

readout. So deck we payers excited the the are have our super as for and payer value to And we're ready proposition go.

So part anything medical coupled we can this before they with in place can taking way discussion the is team change and be actually or do engage will what there. of the payer of label some

to by formulary, just so Cigna, future. excited discussions well we're and as adding as for seen us excited demand payers that evidenced getting we're we've so the certainly And those and for as the are

Paul Choi

that describing for the as or are bempedoic, in oral little more expect you in Okay, down like R&D but timelines I I thinking just about around your you you how the the were Day, a you're for we up at 'XX, great. follow compound year. out starting INDs to to that. PCSKX maybe back half earlier, your expense cadence JoAnne, you'll those a Thanks generation Outcomes guess ACL detail upcoming with there? to the bit trickling Can know should and wind probably longer of sort of of this assets next here speak this CLEAR then potential to operating start assuming And INDs

JoAnne Foody

much. thank you so Paul, So

More we likely PCSKX. as those in Oral as similarly next the with Probably oral about trickle of the I would think rollout, XXXX is that look right platform the word. at acid across out for opportunities the be we in would where ACLi, of would anticipate think platform Outcomes study hinged likely very probably too the A bempedoic earliest as that. indications with we be think we would the on we about depending it, of stand bulk more approach. prioritizing there, after on think well end but lot the to as potential PCSKX, the the and is respect XXXX. again, generation XXXX,

Paul Choi

our taking for Thanks questions. great. Okay,

Sheldon Koenig

Thanks, Paul.

Operator

showing sir. Thank you. [Operator I'm the in Instructions]. And not any queue, questions further

Sheldon Koenig

of we've for CLEAR MACE-X I questions. on The of the fact XXX% excited about all accumulated trial the accumulation. for to your is those of again step Outcomes wanted the the with line and extremely what you one first your we've to Great. just getting thank interest organization announced realizing today that closer

a again all you have So thank great day. and

Operator

Ladies may this call. And you participating. today's for and conference you. gentlemen, disconnect. now Thank you Thank concludes

Esperion Therapeutics (ESPR) 2 Aug 222022 Q2 Earnings call transcript